We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
NICE did not recommend the treatment due to uncertainty about how stopping the treatment and quality of life affect its cost-effectiveness estimates. Read More
Sarclisa was previously approved in the U.S in combination with pom-dex for the treatment of adults with relapsed refractory multiple myeloma. Read More
The approval is the first for aspirin plus Brilinta in patients who have a high cardiovascular risk without a history of heart attack or stroke. Read More
The EMA’s Committee for Medicinal Products for Human Use (CHMP) recommended eight new drugs for approval at its May meeting, including Johnson and Johnson’s Ebola vaccine. Read More